Literature DB >> 33943067

Successful treatment of two cases of refractory cutaneous lupus erythematosus with belimumab.

Xavier Bosch-Amate1, Daniel Morgado-Carrasco1, Andrea Combalia1, Priscila Giavedoni1, Gerard Espinosa2, José M Mascaró1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33943067     DOI： 10.25259/IJDVL_1032_18

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN： 0378-6323            Impact factor:   2.545


× No keyword cloud information.
  6 in total

1.  Characteristics and Alternative Treatment Outcomes of Antimalarial-Refractory Cutaneous Lupus Erythematosus.

Authors:  Renee Fruchter; Drew J B Kurtzman; Mital Patel; Joseph Merola; Andrew G Franks; Ruth Ann Vleugels; Alisa N Femia
Journal:  JAMA Dermatol       Date:  2017-09-01       Impact factor: 10.282

2.  High expression of B lymphocyte stimulator in lesional keratinocytes of patients with cutaneous lupus erythematosus.

Authors:  Joerg Wenzel; Aysche Landmann; Gero Vorwerk; Annegret Kuhn
Journal:  Exp Dermatol       Date:  2017-11-28       Impact factor: 3.960

3.  Belimumab for the treatment of recalcitrant cutaneous lupus.

Authors:  P Vashisht; K Borghoff; J R O'Dell; M Hearth-Holmes
Journal:  Lupus       Date:  2016-12-13       Impact factor: 2.911

4.  The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation.

Authors:  Carina Götestam Skorpen; Maria Hoeltzenbein; Angela Tincani; Rebecca Fischer-Betz; Elisabeth Elefant; Christina Chambers; Josè da Silva; Catherine Nelson-Piercy; Irene Cetin; Nathalie Costedoat-Chalumeau; Radboud Dolhain; Frauke Förger; Munther Khamashta; Guillermo Ruiz-Irastorza; Angela Zink; Jiri Vencovsky; Maurizio Cutolo; Nele Caeyers; Claudia Zumbühl; Monika Østensen
Journal:  Ann Rheum Dis       Date:  2016-02-17       Impact factor: 19.103

5.  Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.

Authors:  Susan Manzi; Jorge Sánchez-Guerrero; Joan T Merrill; Richard Furie; Dafna Gladman; Sandra V Navarra; Ellen M Ginzler; David P D'Cruz; Andrea Doria; Simon Cooper; Z John Zhong; Douglas Hough; William Freimuth; Michelle A Petri
Journal:  Ann Rheum Dis       Date:  2012-05-01       Impact factor: 19.103

6.  Belimumab: First targeted biological treatment for systemic lupus erythematosus.

Authors:  Ashok K Dubey; Shailendra S Handu; Suparna Dubey; Prashant Sharma; K K Sharma; Qazi M Ahmed
Journal:  J Pharmacol Pharmacother       Date:  2011-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.